AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
6 articles.
Bangladesh All Bangladesh research →
Company · DSE:SINOBANGLA · Plastics and packaging: FIBC and woven polypropylene bags · Analysis · 02 Nov 2026
Sinobangla Industries: FY2025 turnover of BDT 2,865m was a ten-year high, with net margin of 1.3% and BDT 92.8m of financial expenses
A Munshiganj maker of jumbo bags (FIBC) and woven polypropylene bags; exports were 95% of FY2025 gross sales. Turnover rose 22.6% in FY2025, nine-month turnover to March 2026 fell 2.1%, and the board announced FY2026 EPS of BDT 1.34 and an 11% cash dividend on 29-Oct-2026.
Company · DSE:FORTUNE · Footwear & leather · Analysis · 31 Oct 2026
Fortune Shoes: auditor disclaimed the FY2025 accounts; 9M FY2026 revenue BDT 839.3m, down 55%
A 100% export shoe maker in Barishal with FY2025 revenue of BDT 2,513.3m and profit of BDT 18.0m. The auditor gave a disclaimer of opinion on the FY2025 accounts, citing BDT 756.0m of cash withdrawals it could not substantiate. The nine months to March 2026 show revenue of BDT 839.3m and a loss of BDT 148.9m.
Company · DSE:LEGACYFOOT · Footwear & leather · Analysis · 31 Oct 2026
Legacy Footwear: revenue BDT 55.8m against BDT 300m in FY2019; FDR interest exceeded pre-tax profit
A 100% export shoe maker that nearly stopped selling in FY2023 (revenue BDT 1.76m) raised its share capital to BDT 430.8m, settled its Rupali Bank loan and is rebuilding volume: FY2025 revenue rose to BDT 55.8m and 9M FY2026 revenue more than doubled, while the BDT 7.1m of FDR interest was larger than the BDT 3.8m profit before tax.
Company · DSE:APEXFOOT · Footwear & leather · Analysis · 31 Oct 2026
Apex Footwear: finance cost takes 79% of operating profit, so a 30% gross margin leaves a 1% net margin
Exports fell 32.5% in FY2024 and came back in FY2026 (Q3 export sales +40.3%), domestic retail kept growing, and FY2026 profit rose 15% to BDT 155m; the auditor qualified the FY2025 accounts over BDT 827m of capitalised borrowing costs.
Company · DSE:RENATA · Pharmaceuticals · Initiation · 29 Oct 2026
Renata's FY2026 recovery is real, but a 10% return on equity supports BDT 146–350 a share (base 234)
Fair value BDT 146–350 (base 234) vs price 425.9 on 29-Oct-2026. FY2026 EPS rose 64% to BDT 31.76 as debt fell; DGDA price controls, a weaker taka on imported APIs and LDC/TRIPS are the risks.
Fair value ৳146–350 · price ৳425.90 (2026-10-29)
Company · DSE:BXPHARMA · Pharmaceuticals · Initiation · 29 Oct 2026
Beximco Pharmaceuticals: fair value BDT 99–218 as FY2026 EPS rises 30% to BDT 20.17
Fair value BDT 99–218 (base 179) against a price of BDT 143.7. Domestic brands, exports and a falling materials bill lift EPS to BDT 28.7 by FY2029F; governance volatility (beta 1.46) and a weaker taka are the risks.
Fair value ৳99–218 · price ৳143.70 (2026-10-29)